This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA
by Zacks Equity Research
Roche's (RHHBY) sBLA for the label expansion of Tecentriq in combination with Abraxane for the initial treatment of NSCLC has been accepted by the FDA.
Stock Market News For Jan 15, 2019
by Zacks Equity Research
Benchmarks ended in the red on Monday as corporate earnings kicked off.
5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
by Zacks Equity Research
Exelixis (EXEL) lead drug, Cabometyx continues to perform well.
What's in Store for Merck in 2019 After a Solid Run in '18?
by Zacks Equity Research
Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
NASH Space in Focus in 2019 as Firms Look to Diversify
by Zacks Equity Research
NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.
5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
by Zacks Equity Research
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Dow 30 Stock Roundup: Boeing Q4 Commercial Deliveries Up Y/Y, Merck Buys NASH Candidate
by Swarup Gupta
The index enjoyed an excellent run this week and has now gained over five successive trading sessions.
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
by Kinjel Shah
Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
by Zacks Equity Research
Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
Moderna (MRNA) Announces Pipeline Progress, Shares Rise
by Zacks Equity Research
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
Novartis' Crizanlizumab Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.
Dow Posts Longest Winning Run Since November: 5 Top Picks
by Nalak Das
The Dow - commenced 2019 on a brighter note. Positive developments on trade war front and Fed???s monetary stance are likely to boost investor sentiment in the near-term resulting in further consolidation of the index.
Dogs of the Dow Win in 2018: Will ETFs See Success in 2019?
by Sanghamitra Saha
Dogs of the Dow beat the broader market in 2018. Will Dogs ETFs be able to taste success this year too?
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $75.43 in the latest trading session, marking a -1.1% move from the prior day.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Gilead (GILD) Collaborates With Yuhan for NASH Candidates
by Zacks Equity Research
Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Bristol-Myers to Acquire Leading Biotech Celgene for $74B
by Zacks Equity Research
Bristol-Myers (BMY) announces an agreement to acquire leading biotech player, Celgene, for a whopping $74 billion.
Pfizer Begins Pivotal Study on Alopecia Areata Candidate
by Zacks Equity Research
Pfizer (PFE) initiates a pivotal phase IIb/III study to evaluate JAK3 inhibitor, PF-06651600, for treating moderate to severe alopecia areata.
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan
by Zacks Equity Research
Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Bristol-Myers' (BMY) Sprycel Gets FDA Nod for Label Expansion
by Zacks.com
Bristol-Myers' (BMY) obtains FDA approval for the label expansion of leukemia drug Sprycel to include pediatric population.
Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy
by Zacks Equity Research
Horizon Pharma's (HZNP) share price increases about 28% based on its business expansion plan and acquisitions.
The Zacks Analyst Blog Highlights: Merck, Abbott, Lockheed Martin, United Parcel Service and Bank of New York Mellon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Abbott, Lockheed Martin, United Parcel Service and Bank of New York Mellon